What 4 Analyst Ratings Have To Say About bluebird bio
Portfolio Pulse from Benzinga Insights
Four analysts have recently provided ratings for bluebird bio (NASDAQ:BLUE), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target is $4.25, down 26.09% from the prior average. Analysts have adjusted their ratings and price targets, reflecting their responses to recent developments. bluebird bio has shown significant revenue growth but faces challenges in profitability, return on equity, and debt management.
August 15, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts have mixed ratings for bluebird bio, with an average price target of $4.25, down 26.09%. The company shows strong revenue growth but faces challenges in profitability, return on equity, and debt management.
The mixed analyst ratings and lowered price targets indicate uncertainty about bluebird bio's short-term performance. Despite strong revenue growth, challenges in profitability and high debt levels may weigh on investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100